149 related articles for article (PubMed ID: 3934800)
1. Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates.
Heldebrant CM; Gomperts ED; Kasper CK; McDougal JS; Friedman AE; Hwang DS; Muchmore E; Jordan S; Miller R; Sergis-Davenport E
Transfusion; 1985; 25(6):510-5. PubMed ID: 3934800
[TBL] [Abstract][Full Text] [Related]
2. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.
Prince AM; Horowitz B; Brotman B
Lancet; 1986 Mar; 1(8483):706-10. PubMed ID: 2870224
[TBL] [Abstract][Full Text] [Related]
3. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
Mannucci PM
Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
[TBL] [Abstract][Full Text] [Related]
5. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
Lancet; 1988 Oct; 2(8615):814-6. PubMed ID: 2902265
[TBL] [Abstract][Full Text] [Related]
6. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
7. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates.
Hart HF; Hart WG; Crossley J; Perrie AM; Wood DJ; John A; McOmish F
Vox Sang; 1994; 67(4):345-50. PubMed ID: 7701804
[TBL] [Abstract][Full Text] [Related]
8. Reduction in risk of hepatitis transmission by heat-treatment of a human Factor VIII concentrate.
Hollinger FB; Dolana G; Thomas W; Gyorkey F
J Infect Dis; 1984 Aug; 150(2):250-62. PubMed ID: 6432922
[TBL] [Abstract][Full Text] [Related]
9. Infection with hepatitis G virus among recipients of plasma products.
Jarvis LM; Davidson F; Hanley JP; Yap PL; Ludlam CA; Simmonds P
Lancet; 1996 Nov; 348(9038):1352-5. PubMed ID: 8918279
[TBL] [Abstract][Full Text] [Related]
10. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus associated DNA polymerase inactivation in factor IX concentrates.
Mitra G; Ng PK
Thromb Res; 1986 Feb; 41(3):291-300. PubMed ID: 3705011
[TBL] [Abstract][Full Text] [Related]
12. The impact of hepatitis C antibody screening of source plasma donors on hepatitis C virus RNA in factor VIII concentrates.
Berntorp E; Lethagen S; Nordenfelt E; Månsson AS; Månsson S; Widell A
Haemophilia; 1995 Oct; 1(4):249-54. PubMed ID: 27214632
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].
Guerois C; Parquet A; Vicariot M; Lecoeur FF; Maisonneuve P; Courouce AM; Dubois F; Laurian Y
Presse Med; 1991 Jun; 20(25):1163-6. PubMed ID: 1830653
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis G virus in clotting factor concentrates.
Alonso-Rubiano E; Gerber M; Friedman P; Hodges S; Leissinger C
Haemophilia; 2003 Jan; 9(1):110-5. PubMed ID: 12558787
[TBL] [Abstract][Full Text] [Related]
15. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
Teh LC; Woodfield DG
Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
[No Abstract] [Full Text] [Related]
16. Hepatitis B virus, hepatitis non-A, non-B virus and hepatitis delta virus in lyophilized antihemophilic factor: relative sensitivity to heat.
Purcell RH; Gerin JL; Popper H; London WT; Cicmanec J; Eichberg JW; Newman J; Hrinda ME
Hepatology; 1985; 5(6):1091-9. PubMed ID: 3934060
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition.
Lusher JM
Am J Med; 1991 Nov; 91(5A):30S-34S. PubMed ID: 1746594
[TBL] [Abstract][Full Text] [Related]
18. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
19. Transmission of hepatitis B by dry heat treated factor VIII and IX concentrates.
Lush CJ; Chapman CS; Mitchell VE; Martin C
Br J Haematol; 1988 Jul; 69(3):421. PubMed ID: 3136793
[No Abstract] [Full Text] [Related]
20. Recovery and inactivation of infectious retroviruses from factor VIII concentration.
Levy JA; Mitra G; Mozen MM
Lancet; 1984 Sep; 2(8405):722-3. PubMed ID: 6148474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
